Objective: This network meta-analysis will provide a complete toxicity profile, toxicity profile, and safety ranking of immune checkpoint inhibitors (ICIs) for treatment of advanced non-small cell lun
Dermal fibroblasts that were cultured from skin biopsy samples were treated for three days with either 1µM of erlotinib, 1µM of DMSO (vehicle), or no treatment. The cells were harvested on the fourth
Objective: To analyze the situation and clinical characteristics of adverse drug reactions (ADRs) induced by camrelizumab, and provide references for clinical medication safety. Methods: Adverse drug